N@N

Trimedyne's Chairman Interviewed by Wall Street Reporter

^{Published on 2009-12-11 10:37:18 - Market Wire}
 

LAKE FOREST, CA--(Marketwire - December 11, 2009) - TRIMEDYNE, INC. (OTCBB: [ TMED ]) today announced its chairman, Dr. Marvin P. Loeb, was interviewed live by the Wall Street Reporter.

The audio interview will only be available on December 11, 2009. To access the live interview, go to[ http://www.wallstreetreporter.com/2009/12/trimedyne-otc-bb-tmed-ceo-interview/ ] on December 11, 2009.

Dr. Loeb discussed the Company's earlier reported increases in revenues, its business and markets, as well as other matters.

Commenting on the interview, Dr. Loeb said, "We are pleased that Wall Street Reporter is alerting the investment community on the potential of Trimedyne's outpatient laser procedures to treat herniated or ruptured discs in the spine, enlarged prostates in men and other conditions."

About Wall Street Reporter

Wall Street Reporter, Inc. is a leading online, market news provider that brings current news and market insight to investors and features one-on-one live interaction with executives of promising, publicly-held companies.

About Trimedyne, Inc.

Trimedyne is a leading manufacturer of proprietary medical lasers and patented fiber optic devices for performing a variety of minimally invasive procedures as a less traumatic, lower cost alternative to traditional surgery. For additional information, visit Trimedyne's website at[ http://www.trimedyne.com ].

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release and the above mentioned interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "expect," "may," "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's Form 10-K-SB for the year ended September 30, 2008 and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.